retatrutide type 2 diabetes phase 2 lancet 2023 rosenstock Incretin-Based Multi-Agonist Therapies for Mellitus and Obesity: Mechanisms, Clinical Efficacy, and Future Directions Retatrutide: A Triple Agonist Shaping

IgG of the same species as the endogenous antibody was used as a negative control

A detailed thyroid history is essential, including diagnosis date, current levothyroxine dosage, recent TSH and free T4 levels, presence of thyroid nodules, history of thyroid surgery or radioactive iodine treatment, and any family history of thyroid cancer or MEN 2 syndrome

Inno Shred GLP-1 may be suitable for those hesitant to try prescription medication

These include: Nausea Vomiting Diarrhoea Constipation Decreased appetite (which, whilst therapeutically intended, can occasionally be excessive) Injection-site reactions (such as redness, bruising, or discomfort at the injection site) These effects were generally mild to moderate in severity and most frequently occurred during the dose-escalation phase of treatment, tending to diminish over time

Opens in a new tab Pinto M, Brennan L, et.al

Post-Approval Experience: While all adverse reactions are not reported, the following adverse reactions are based on voluntary post-approval reporting for LEGEND Injectable Solution: Following Intravenous use: Occasional depression, lethargy, and fever